Journal Guide

Due to the plethora of new approaches being used in modern drug discovery by the pharmaceutical industry, Current Drug Discovery Technologies has been established to provide comprehensive overviews of all the major modern techniques and technologies used in drug design and discovery. The journal is the forum for publishing original research papers, reviews, drug clinical trial studies and guest edited thematic issues describing novel approaches and cutting edge technologies used in all stages of drug discovery. The journal addresses the multidimensional challenges of drug discovery science including integration issues of the drug discovery process.

Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism.
More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites. Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes.

Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.

Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy and drug clinical trial studies and guest edited thematic issues covering: new and existing drugs, therapies and medical devices.

Current Enzyme Inhibition aims to publish original research, review and letter articles in all the latest and outstanding developments on enzyme inhibition studies. The coverage includes the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Current Enzyme Inhibition is an essential journal for every pharmaceutical researcher and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.

Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of genetic diseases. Cell therapy manuscripts can also include application in non-genetic diseases when cells have been genetically modified. Current Gene Therapy publishes reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of genetic diseases.

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Current Molecular Pharmacology aims to publish the latest developments in cellular and molecular pharmacology with a major emphasis on the mechanism of action of novel drugs under development, innovative pharmacological technologies, cell signaling, transduction pathway analysis, genomics, proteomics, and metabonomics applications to drug action. An additional focus will be the way in which normal biological function is illuminated by knowledge of the action of drugs at the cellular and molecular level. The journal publishes expert reviews , original research articles and thematic issues on molecular pharmacology.

Current Nanoscience publishes (a) Authoritative/Mini Reviews, and (b) Original Research and Highlights written by experts covering the most recent advances in nanoscience and nanotechnology. All aspects of the field are represented including nano-structures, nano-bubbles, nano-droplets and nanofluids. Applications of nanoscience in physics, material science, chemistry, synthesis, environmental science, electronics, biomedical nanotechnology, biomedical engineering, biotechnology, medicine and pharmaceuticals are also covered. The journal is essential to all researches involved in nanoscience and its applied and fundamental areas of science, chemistry, physics, material science, engineering and medicine.

Current Nanotoxicity and Prevention aims to provide an interdisciplinary forum for researchers and practitioners, to share innovative research and engineering practices that prevent nano-toxicity.

The journal also aims to explore how innovative methods are used for detection, evaluation and mitigating nanotoxicity. In addition, new safety regulations for manufacturer/application/disposal/exposure of nanomaterials will be proposed in the journal.

Current Neuropharmacology aims to provide current, timely and comprehensive reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience.

The Current Opinion journals were developed out of the recognition that it is increasingly difficult for specialists to keep up to date with the expanding volume of information published in their subject. In Current Opinion in Pharmacology, we help the reader by providing in a systematic manner:1. The views of experts on current advances in pharmacology in a clear and readable form.2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publicationsDivision of the subject into sectionsThe subject of pharmacology is divided into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance.Neurosciences • Cardiovascular and renal • Respiratory • Musculoskeletal • Cancer • Immunomodulation • Anti-infectives • New technologies • Gastrointestinal • Endocrine and metabolic diseasesSelection of topics to be reviewedSection Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.ReviewsAuthors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.Editorial OverviewSection Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest

Current Pharmaceutical Analysis publishes expert reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews, research articles and letters written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary peer-reviewed biomedical journal that reports new findings and cutting-edge concepts in both pharmacogenomics and personalized medicine under a single cover. CPPM is an accelerator for global personalized medicine and pharmacogenomics. Importantly, the journal provides a multi-disciplinary integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries.